Truqap (capivasertib) is an oral selective adenosine triphosphate (ATP) competitive inhibitor of all three isoforms of the serine/threonine kinase AKT (AKT 1/2/3), which is designed to work by targeting mutations in the AKT1 gene, which is responsible for tumor growth and proliferation [117,118]. Here, AKT1 is linked to neoplasm.